Alpine Immune Sciences

Alpine Immune Sciences FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Alpine Immune Sciences (ALPN) as of Nov 17, 2026 is 247.01 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 76.46 % — a change of 223.05% (higher).

FCF Conversion

247.01 %

YoY

223.05%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Alpine Immune Sciences is 2023 247.01 % . FCF Conversion Rate (FCF/EBITDA) of Alpine Immune Sciences was 2022 76.46 % . It decreases by 223.05% higher compared to the previous year.

The Alpine Immune Sciences FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2016
83.80 USD
Jan 1, 2017
220.45 USD
Jan 1, 2018
79.24 USD
Jan 1, 2019
85.03 USD
Jan 1, 2020
-104.80 USD
Jan 1, 2021
30.53 USD
Jan 1, 2022
76.46 USD
Jan 1, 2023
247.01 USD
The Alpine Immune Sciences FCF Conversion history
YEARFCF ConversionYoY
247.01 %+223.05%
76.46 %+150.46%
30.53 %-129.13%
-104.80 %-223.25%
85.03 %+7.31%
79.24 %-64.06%
220.45 %+163.08%
83.80 %-1.41%
85.00 %-11.57%
96.12 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alpine Immune Sciences Stock analysis

What does Alpine Immune Sciences do? Alpine Immune Sciences Inc. is a biopharmaceutical company specializing in the research and development of immunotherapies. Founded in 2015, the company is based in Seattle, Washington and holds numerous patents in the field of immunology. Alpine's business model is to utilize clinical science and innovative technologies to revolutionize immunotherapy. The company combines antibodies and other immunological agents to significantly improve the effectiveness and safety of therapies. The company is divided into several divisions, each offering different products and services. One division focuses on the discovery of novel antibodies and other biological agents. Through various technology platforms, Alpine continuously develops groundbreaking therapies that have the potential to revolutionize the treatment of cancer, autoimmune diseases, and other illnesses. Another division of Alpine is dedicated to the field of immuno-oncology, specifically researching and developing immunotherapies against cancer. The main goal is to enhance the body's own immune defenses against cancer cells. Furthermore, Alpine also develops therapies for specific autoimmune diseases, where the body's immune system attacks its own cells and tissues. In this area as well, the company relies on combining different immunological agents to increase the effectiveness and safety of the therapy. One of Alpine's most well-known products is ALPN-101, a novel antibody that can be used in immunotherapy against cancer and autoimmune diseases. This antibody has the potential to improve the effectiveness and safety of existing therapies, contributing to the cure and relief of illnesses. Alpine Immune Sciences Inc. has an impressive track record, having made significant progress in the field of immunotherapy in a short period of time and establishing itself as a leading provider of innovative therapies. Additionally, Alpine has successfully formed partnerships with other companies and institutions to advance its research and development. Overall, Alpine Immune Sciences Inc. represents a forward-thinking and innovative approach to immunotherapy, with the potential to change the lives of millions of people worldwide. Alpine Immune Sciences is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alpine Immune Sciences stock

FCF Conversion Rate (FCF/EBITDA) of Alpine Immune Sciences is 247.01 % in 2023.

FCF Conversion Rate (FCF/EBITDA) of Alpine Immune Sciences changed from 76.46 % to 247.01 %, representing a 223.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Alpine Immune Sciences since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Alpine Immune Sciences with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Alpine Immune Sciences

All Key Metrics — Alpine Immune Sciences